Single-dose YF17D-vectored Ebola vaccine candidate protects mice against both lethal surrogate Ebola and yellow fever virus challenge
Ebola virus (EBOV) and related filoviruses such as Sudan virus (SUDV) threaten global public health. Effective filovirus vaccines are available only for EBOV, yet restricted to emergency use considering a high reactogenicity and demanding logistics. Here we present YF-EBO, a live YF17D-vectored dual-target vaccine candidate expressing EBOV-glycoprotein (GP) as protective antigen. Safety of YF-EBO in mice was further improved over that of parental YF17D vaccine. A single dose of YF-EBO was sufficient to induce high levels of EBOV-GP specific antibodies and cellular immune responses, that protected against lethal infection using EBOV-GP-pseudotyped recombinant vesicular stomatitis virus (rVSV-EBOV) in interferon-deficient (Ifnar-/-) mice as surrogate challenge model. Concomitantly induced yellow fever virus (YFV)-specific immunity protected Ifnar-/- mice against intracranial YFV challenge. YF-EBO could thus help to simultaneously combat both EBOV and YFV epidemics. Finally, we demonstrate how to target other highly pathogenic filoviruses such as SUDV at the root of a current outbreak in Uganda..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 14. Jan. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lemmens, Viktor [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2023.01.13.523888 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI038410117 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI038410117 | ||
| 003 | DE-627 | ||
| 005 | 20230429094303.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230115s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.01.13.523888 |2 doi | |
| 035 | |a (DE-627)XBI038410117 | ||
| 035 | |a (biorXiv)10.1101/2023.01.13.523888 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lemmens, Viktor |e verfasserin |0 (orcid)0000-0003-2507-9029 |4 aut | |
| 245 | 1 | 0 | |a Single-dose YF17D-vectored Ebola vaccine candidate protects mice against both lethal surrogate Ebola and yellow fever virus challenge |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Ebola virus (EBOV) and related filoviruses such as Sudan virus (SUDV) threaten global public health. Effective filovirus vaccines are available only for EBOV, yet restricted to emergency use considering a high reactogenicity and demanding logistics. Here we present YF-EBO, a live YF17D-vectored dual-target vaccine candidate expressing EBOV-glycoprotein (GP) as protective antigen. Safety of YF-EBO in mice was further improved over that of parental YF17D vaccine. A single dose of YF-EBO was sufficient to induce high levels of EBOV-GP specific antibodies and cellular immune responses, that protected against lethal infection using EBOV-GP-pseudotyped recombinant vesicular stomatitis virus (rVSV-EBOV) in interferon-deficient (Ifnar-/-) mice as surrogate challenge model. Concomitantly induced yellow fever virus (YFV)-specific immunity protected Ifnar-/- mice against intracranial YFV challenge. YF-EBO could thus help to simultaneously combat both EBOV and YFV epidemics. Finally, we demonstrate how to target other highly pathogenic filoviruses such as SUDV at the root of a current outbreak in Uganda. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Kelchtermans, Lara |0 (orcid)0000-0002-5631-8101 |4 aut | |
| 700 | 1 | |a Debaveye, Sarah |0 (orcid)0000-0002-3969-1019 |4 aut | |
| 700 | 1 | |a Chiu, Winston |0 (orcid)0000-0001-5236-623X |4 aut | |
| 700 | 1 | |a Vercruysse, Thomas |0 (orcid)0000-0002-8649-777X |4 aut | |
| 700 | 1 | |a Ma, Ji |0 (orcid)0000-0002-0912-2632 |4 aut | |
| 700 | 1 | |a Thibaut, Hendrik Jan |0 (orcid)0000-0001-5785-8276 |4 aut | |
| 700 | 1 | |a Neyts, Johan |0 (orcid)0000-0002-0033-7514 |4 aut | |
| 700 | 1 | |a Sanchez-Felipe, Lorena |0 (orcid)0000-0002-6928-0931 |4 aut | |
| 700 | 1 | |a Dallmeier, Kai |0 (orcid)0000-0002-8117-9166 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 14. Jan. |
| 773 | 1 | 8 | |g year:2023 |g day:14 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.01.13.523888 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 14 |c 01 | ||